Literature DB >> 34127579

Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.

Jesse Fajnzylber1, Radwa Sharaf1, John N Hutchinson2, Evgenia Aga2, Ronald J Bosch2, Wendy Hartogensis3, Jeffrey M Jacobson4, Elizabeth Connick5, Paul Volberding3, Daniel J Skiest6, David Margolis7, Michael C Sneller8, Susan J Little9, Roy M Gulick10, John W Mellors11, Rajesh T Gandhi12, Robert T Schooley9, Keith Henry13, Pablo Tebas14, Steve Deeks3, Tae-Wook Chun8, Ann C Collier15, Frederick M Hecht3, Jonathan Z Li1.   

Abstract

Clinical trials including an analytical treatment interruption (ATI) are vital for evaluating the efficacy of novel strategies for HIV remissions. We briefly describe an interactive tool for predicting viral rebound timing in ATI trials and the impact of posttreatment controller (PTC) definitions on PTC frequency estimates. A 4-week viral load threshold of 1000 cps/ml provides both high specificity and sensitivity for PTC detection. PTC frequency varies greatly based on the definition of a PTC.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 34127579      PMCID： PMC8490281          DOI： 10.1097/QAD.0000000000002978

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.632


  20 in total

1.  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

Authors:  J Michael Kilby; R Pat Bucy; Donna Mildvan; Margaret Fischl; Jorge Santana-Bagur; Jeff Lennox; Chris Pilcher; Andrew Zolopa; Jody Lawrence; Richard B Pollard; Raphaelle El Habib; David Sahner; Lawrence Fox; Evgenia Aga; Ronald J Bosch; Ronald Mitsuyasu
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

2.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

Authors:  Jeffrey M Jacobson; R Pat Bucy; John Spritzler; Michael S Saag; Joseph J Eron; Robert W Coombs; Rui Wang; Lawrence Fox; Victoria A Johnson; Susan Cu-Uvin; Susan E Cohn; Donna Mildvan; Dorothy O'Neill; Jennifer Janik; Lynette Purdue; Deborah K O'Connor; Christine Di Vita; Ian Frank
Journal:  J Infect Dis       Date:  2006-08-01       Impact factor: 5.226

4.  A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.

Authors:  Keith Henry; David Katzenstein; Deborah Weng Cherng; Hernan Valdez; William Powderly; Michelle Blanchard Vargas; Nasreen C Jahed; Jeffrey M Jacobson; Laurie S Myers; John L Schmitz; Mark Winters; Pablo Tebas
Journal:  J Acquir Immune Defic Syndr       Date:  2006-06       Impact factor: 3.731

5.  Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

Authors:  Daniel J Skiest; Zhaohui Su; Diane V Havlir; Kevin R Robertson; Robert W Coombs; Pat Cain; Tianna Peterson; Amy Krambrink; Nasreen Jahed; Deborah McMahon; David M Margolis
Journal:  J Infect Dis       Date:  2007-04-06       Impact factor: 5.226

6.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Authors:  Robert T Schooley; John Spritzler; Hongying Wang; Michael M Lederman; Diane Havlir; Daniel R Kuritzkes; Richard Pollard; Cathy Battaglia; Michael Robertson; Devan Mehrotra; Danilo Casimiro; Kara Cox; Barbara Schock
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

7.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.

Authors:  Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

8.  Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group.

Authors:  J D Stekler; R Wellman; S Holte; J Maenza; C E Stevens; L Corey; A C Collier
Journal:  Int J STD AIDS       Date:  2012-03       Impact factor: 1.359

9.  HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Authors:  Mykola Pinkevych; Deborah Cromer; Martin Tolstrup; Andrew J Grimm; David A Cooper; Sharon R Lewin; Ole S Søgaard; Thomas A Rasmussen; Stephen J Kent; Anthony D Kelleher; Miles P Davenport
Journal:  PLoS Pathog       Date:  2015-07-02       Impact factor: 6.823

10.  A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

Authors:  Rajesh T Gandhi; David O'Neill; Ronald J Bosch; Ellen S Chan; R Pat Bucy; Janet Shopis; Lynn Baglyos; Elizabeth Adams; Lawrence Fox; Lynette Purdue; Ann Marshak; Theresa Flynn; Reena Masih; Barbara Schock; Donna Mildvan; Sarah J Schlesinger; Mary A Marovich; Nina Bhardwaj; Jeffrey M Jacobson
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641
View more
  3 in total

Review 1.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

Review 2.  Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection.

Authors:  Chuen-Yen Lau; Matthew A Adan; Frank Maldarelli
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

Review 3.  Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.

Authors:  Lu Zheng; Camlin Tierney; Ronald J Bosch
Journal:  Curr HIV/AIDS Rep       Date:  2021-07-02       Impact factor: 5.495
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.